Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.48 |
| ▸ | BTK | Q06187 | 10/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719845 | 0.81 | TEAD1 (0.46) | TEAD1BTKJAK3 | |
| SCHEMBL22731938 | 0.80 | TEAD1 (0.49) | TEAD1BTKJAK3 | |
| SCHEMBL22719541 | 0.80 | TEAD1 (0.45) | TEAD1 | |
| SCHEMBL20343567 | 0.76 | HSD11B1 (0.45) | TEAD1BTKJAK3F13A1TGM2 | |
| SCHEMBL4798583 | 0.73 | USP30 (0.38) | — | |
| SCHEMBL21707130 | 0.73 | TEAD1 (0.46) | TEAD1BTKJAK3 | |
| SCHEMBL22461186 | 0.70 | HSD11B1 (0.49) | TEAD1JAK3F13A1TGM2TGM1 | |
| SCHEMBL2824467 | 0.69 | NPC1 (0.56) | F13A1TGM2TGM1 | |
| SCHEMBL3169796 | 0.69 | NPC1 (0.51) | — | |
| SCHEMBL21393276 | 0.68 | TEAD1 (0.36) | TEAD1BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885BTK 1796/4885JAK3 2919/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885BTK 1796/4885JAK3 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.